TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00940095

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 5 m/h
Description: Continuous intravenous infusion of clazosentan (5 mg/h)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clazosentan 15 mg/h
Description: Continuous intravenous infusion of clazosentan clazosentan (15 mg/h)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Continuous intravenous infusion of placebo-matching clazosentan
Study: NCT03818347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oxyhydrogen generator (AMS-H-03)
Description: Rated gas output (L) : 3L/min, concentration of hydrogen and the oxygen was 66.6% and 33.3%, respectively. The patients inhale 3 hours each day through a cannula or mask, and persist for long term

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: analogue machine
Description: This machine has the same apperance and gas condition
Study: NCT00712569

Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.

Intervention type: BEHAVIORAL
Intervention: audio recordings , questionnaires
Description: Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.~However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not.

Intervention type: BEHAVIORAL
Intervention: audio recorded questionnaires
Description: Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
Study: NCT04072679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab+IBI305
Description: It includes dose escalation and dose expansion stage. 6-9 subjects will be enrolled in dose escalation stage for the safety and efficacy evaluation. Then select specific dose of IBI305 +Sintilimab 200mg/kg, expand to 36-39 patients for the further safety and efficacy study.The study treatment lasts up to 24 months.
Study: NCT01110837

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Allergen nasal challenge

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo challenge
Description: Placebo nasal challenge
Study: NCT02593812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stepping training
Description: Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Stepping training
Description: Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
Study: NCT00066469

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Cycles 1 and 2 only: Given IV Incremental: First dosage: \< 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: \< 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
Study: NCT04092907

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HBM9036 0.25% Ophthalmic Solution
Description: Ophthalmic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Ophthalmic Solution
Study: NCT03292419

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Topography-guided LASIK
Description: LASIK surgery
Study: NCT00837824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 1.0 mg/kg every 2 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabrazyme (agalsidase beta)
Description: 3.0 mg/kg every 2 weeks
Study: NCT01483534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TLD Therapy (IPS SystemTM)
Description: Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
Study: NCT02181101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC-DocGemzar adjuvant chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC-DocGemzar adjuvant chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FEC-Doc adjuvant chemotherapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FEC-Doc adjuvant chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid i.v. 2 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid i.v. 2 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid i.v. 5 years

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid i.v. 5 years
Study: NCT00762567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenylephrine HCl
Description: A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
Study: NCT02723006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-580
Description: TAK-580 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-202
Description: TAK-202 infusion
Study: NCT03195803

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Stimulation
Description: All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized Cognitive Stimulation
Description: All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
Study: NCT01562379

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rice based complementary food supplement
Description: Locally developed rice based complementary food with and added vitamins and minerals.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plumpy Doz
Description: Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
Study: NCT04471532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior change intervention
Description: It is a 3-month, multimodal, minimal contact, pedometer-driven, behavior change intervention to promote and support physical activity, that is initiated 3 months after THA. There is one initial, physiotherapist-led, face-to-face, physical activity counselling including 1) a brief motivational interviewing regarding physical activity, 2) patient education regarding physical activity after THA including recommendations and safety based on an orthopedic surgeon guided video and leaflet, 3) handling out pedometer and educational material i.e. a practice-oriented leaflet with advice on how to use a pedometer, a step-calendar and goal setting as well as strategies to incorporate physical activity into daily life. This initial counselling is followed by two, physiotherapist-led, telephone-assisted counselling after respectively three and seven weeks.
Study: NCT01814228

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcatheter ablation of ganglionated plexi in right atrium
Study: NCT01023139

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sibutramine
Description: During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
Study: NCT02621281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Kidney Transporter machines
Description: Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
Study: NCT02723006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vedolizumab
Description: vedolizumab infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab infusion
Study: NCT02621281

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cold storage
Description: The kidneys procurement from the donor will be cold stored using some cold preservation solution.
Study: NCT03139773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Breakfast Beverage
Description: Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
Study: NCT02723006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: nivolumab infusion
Study: NCT03139773

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control Breakfast Beverage
Description: Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Breakfast Beverage
Description: Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 Breakfast Beverage
Description: Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
Study: NCT04495322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG-1000
Description: Subjects will receive one single oral dose of TG-1000 on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
Study: NCT04495322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will receive one single oral dose of placebo on day 1 following protocol requirements.
Study: NCT00906555

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modification of hemodialysis parameters on dialysis machine
Description: Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
Study: NCT02597348

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Transplantation
Description: The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
Study: NCT00731289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid
Description: one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
Study: NCT04744766

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: major duct excision
Description: 2 methods of major/central mammary duct excision are compared as regard the outcome

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: major duct excision
Description: 2 methods of major/central mammary duct excision are compared as regard the outcome
Study: NCT02112149

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LIVESTRONG
Description: The LIVESTRONG at the YMCA is a twelve-week, small group (\< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
Study: NCT04528693

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Circuit training (combination of strength and endurance exercises)
Description: The intervention will last 3 months, exercises will take place 3 times a week and will consist of strength exercises, interspersed with bouts of endurance exercise carried out on circuit machines integrated with the Milon computer software for a total of 30 minutes per session.
Study: NCT03153124

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory muscle training
Description: The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
Study: NCT00779597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCION (Self care improvement through oncology nursing)-PAIN program
Description: The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
Study: NCT02350192

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-health educational intervention (eHEI)
Description: The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
Study: NCT00443534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SU011248
Description: Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
Study: NCT04475029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: One intravenous administration of methadone (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: One intravenous administration of morphine (0.15 mg/kg treatment weight (height(cm)-100)) one hour prior to expected extubation.
Study: NCT02723006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: ipilimumab infusion
Study: NCT01711229

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV acetaminophen
Description: Ofirmev will be given 15 minutes prior to going to the OR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral acetaminophen
Description: oral acetaminophen will be given preoperatively
Study: NCT03350139

Intervention type: DEVICE
Intervention: gamma knife radiosurgery
Description: The surgical procedure consists of a very partial radiation of the brain with a stereotactic precision performed in current practice
Study: NCT00439699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Mematine administration
Study: NCT01448824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally
Study: NCT04262557

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sunrise® solution
Description: Type II medical device with the CE label. It is a chin sensor associated to an integrated and connected platform.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Gold standard method to diagnose SAS used as comparator
Study: NCT03481296

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Control
Description: Participants receive linguistically and culturally tailored information booklet on colorectal cancer and colorectal cancer screening, colonoscopy instructions, stool blood test kits and reminder by mail. Participants' height, weight, and waist/hip circumference, blood pressure, blood glucose, and cholesterol levels will be measured by trained research staff. Participants will also receive the result of body measurements right away as a free service.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally-Adapted Decision Support Navigation Intervention
Description: Participants in this group receive everything that advanced control group receives. In addition to a set of standard materials, they receive culturally and linguistically adapted decision counseling from the patient navigator. The patient navigator develops an individualized colorectal cancer screening plan using a theory-based online Decision Counseling Program. After the Program is completed, the patient navigator develops individualized colorectal cancer screening plan and shares the information with participants and participants' primary care physicians. Then, primary care physicians encourage the colorectal cancer screening to participants.
Study: NCT02893332

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: SBRT
Description: A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
Study: NCT01448824

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2484595
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally
Study: NCT02893332

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TKI (Gefitinib or Tarceva )
Description: A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TKI (Gefitinib or Tarceva )
Description: A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
Study: NCT04429828

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19 e-package: Psychological wellbeing for healthcare workers
Description: All healthcare students have access to a COVID-19 educational learning package around psychological wellbeing (usual practice). In this study the investigators will conduct semi-structured qualitative interviews with healthcare students about their mental wellbeing, and use of this e-package.